Get the latest Science News and Discoveries

Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk


A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer. Researchers say the findings are promising but not yet proof, and clinical trials are now being planned to test whether these drugs could help prevent breast cancer.

None

Get the Android app

Or read this on ScienceDaily

Read more on:

Photo of loss drugs

loss drugs

Related news:

News photo

Popular GLP-1 weight-loss drugs linked to lower risks of addiction and overdose

News photo

Popular GLP-1 weight-loss drugs like Ozempic slash heart attack and stroke risk

News photo

Quitting weight-loss drugs or a diet can cause weight regain—two strategies could help prevent that